Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00485407
First received: June 11, 2007
Last updated: October 31, 2007
Last verified: June 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2005
  Estimated Primary Completion Date: No date given